TherapeuticsMD™, Inc. (OTCQB: TXMD), parent company of vitaMedMD®,
LLC ("vitaMedMD"), a specialty pharmaceutical company ("TherapeuticsMD"
or the "Company"), announced that on May 10, 2012 it launched its third
prescription prenatal vitamin, vitaMedMD™ RediChew™ Rx, following
the successful launch of vitaMedMD™ One Rx earlier this month and
vitaMedMD™ Plus Rx last month. vitaMedMD RediChew Rx is a
small, vanilla flavored, chewable prenatal vitamin tablet that dissolves
quickly and is taken once daily.
Like vitaMedMD Plus Rx and vitaMedMD One Rx, vitaMedMD
RediChew Rx contains the same unique combination of folic acid and
the patent-protected fourth generation folate, Quatrefolic®.
With the addition of Quatrefolic, all three vitaMedMD Rx prenatal
vitamins have the potential to further reduce the devastating impact of
folic acid related deficiencies such as spina bifida and anencephaly.
Jason Spitz, Vice President of Marketing for TherapeuticsMD, stated, "vitaMedMD
RediChew Rx provides a great option for pregnant women who have
difficulty swallowing tablets or capsules, or where nausea or morning
sickness make taking tablets or capsules difficult. vitaMedMD
RediChew Rx is also a suitable daily multivitamin choice for all
women of childbearing age, as it provides the folic acid recommended by
the U.S. Public Health Service, CDC, and the March of Dimes. With the
addition of Quatrefolic, vitaMedMD prescription prenatals provide a
'body ready' form of folate, which is especially important for women
with MTHFR polymorphisms who may not be able to fully metabolize
synthetic folic acid. vitaMedMD RediChew Rx also contains
vitamins B6 and B12, which may help relieve nausea and morning sickness."